ArticleClinical pharmacology and therapeutics2026
Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy-associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal-fetal safety of systemic anticancer therapies is critical. We performed a case/non-case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal-fetal outcomes associated with breast cancer (BC) systemic treatments. The exposure group consisted of reports mentioning a BC treatment at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal-fetal complications with the two cornerstone cytotoxic classes, anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel, paclitaxel), assessed individually vs. other anticancer treatments. Secondary analyses assessed all BC treatments and trimester-specific risks. Of 3310 pregnancy-related reports, 1789 involved BC treatments. Median maternal age was 27.4 years (SD 13.8) vs. 29.3 (SD 11.7) in the comparator group. Adverse maternal-fetal outcomes were reported in 998 (55.8%) BC treatment reports vs. 470 (30.9%) in other anticancer treatments. Anthracyclines were associated with neonatal hematologic disorders (ROR = 1.7, 95% CI = 1.1-2.5) and intrauterine growth restriction (IUGR) (ROR = 2.1, 95% CI = 1.7-2.7). Paclitaxel was linked to sensory defects including congenital ear/ocular anomalies (ROR = 5.2, 95% CI = 2.2-12.3); all 8 cases involved platinum co-exposure (cisplatin: n = 5; carboplatin: n = 3), suggesting a platinum-mediated mechanism; and to hyperbilirubinemia (ROR = 4.1, 95% CI = 2.0-8.4), and docetaxel to neonatal neurologic disorders (ROR = 3.6, 95% CI = 1.4-9.3). First-trimester exposure (n = 26) showed preliminary signals of increased congenital malformation risk, including face (ROR = 13, 95% CI = 2-79), and musculoskeletal malformation (ROR = 8, 95% CI = 1.1-60). This pharmacovigilance study identifies signals of disproportionate reporting of specific maternal and neonatal outcomes with BC treatments; these findings are hypothesis-generating and require confirmation in prospective registries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.